News for Fortress Biotech, Inc. (FBIO)

Sun Pharma, India's largest pharmaceutical company, is set to acquire Checkpoint Therapeutics for $355 million. This strategic acquisition will enhanc

Sun Pharma acquires Checkpoint Therapeutics for $355 million, expanding its oncology portfolio with innovative treatments.

PR NewswireMUMBAI, India and WALTHAM, Mass., March 9, 2025 Will add UNLOXCYTâ„¢ (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment fo

Sun Pharmaceutical announced the acquisition of Nasdaq-listed Checkpoint Therapeutics, an immunotherapy and oncology company. The deal involves an upfront cash payment of $4.10 per share, totaling up to $355 million, with additional potential payouts based on milestones. The acquisition strengthens Sun Pharma's innovative portfolio in onco-derm therapy, particularly for advanced cutaneous squamous cell carcinoma.

**media[558457]**

U.S. FDA approved Emrosiâ„¢ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the treatment o

WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (”œMustang” or the ”œCompany”) ( MBIO), a clinical-stage biopharmaceutical company f

**media[538133]**

**media[536656]**

Study is the first randomized, controlled trial examining a vaccine's effectiveness in controlling CMV in recipients of HSCT from vaccinated donors Encouraging

Mustang Bio stock plunges to 52-week low of $0.13

WORCESTER, Mass., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (

Stocks including Indo Farm Equipment, Bharti Airtel, Power Grid, Coal India, Vakrangee, IndiGo, Zydus Life, Vodafone Idea, NMDC and more will be in the spotlight on Tuesday, January 07.

PR NewswireSOLANA BEACH, Calif. and AHMEDABAD, India and MIAMI, Jan. 6, 2025 Six-month priority review granted for CUTX-101 copper histidinate with PDUFA t

UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma WALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIR

**media[491851]**

The FDA has approved 43 novel drugs so far this year (January-November), compared to 52 during the same period last year. As we step into the final month of the year, let's take a look at the biotech companies whose drugs are under regulatory review in the U.

**media[466685]**

**media[464121]**